Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOLA: Osimertinib induction before chemoradiotherapy followed by osimertinib maintenance in unresectable stage III EGFR-mutated NSCLC
MOH_2024-02-14_013147Phase 2Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on MOH_2024-02-14_013147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-14_013147.